enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.660
-0.010 (-0.60%)
Oct 21, 2026, 11:01 AM EDT - Market open
enGene Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, enGene Therapeutics stock has a consensus rating of "Hold" and an average price target of $3.29. The average 1-year stock price forecast is 98.19% higher than the current stock price, while the lowest is $2.00 (+20.48%) and the highest is $5.00 (+201.20%).
Price Target: $3.29 (+98.19%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for enGene Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 8 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $4 | Buy | Reiterates | $4 | +140.96% | Oct 16, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $4 | Hold | Maintains | $4 | +140.96% | Oct 16, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $2 | Hold | Maintains | $2 | +20.48% | Oct 2, 2026 |
| UBS | UBS | Hold Reiterates $2 | Hold | Reiterates | $2 | +20.48% | Sep 16, 2026 |
| Leerink Partners | Leerink Partners | Hold Reiterates $2 | Hold | Reiterates | $2 | +20.48% | Sep 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
6.17M
EPS This Year
-1.81
from -2.29
EPS Next Year
-1.45
from -1.81
EPS and Forward PE are based on non-GAAP adjusted numbers.